Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL635664 | 0.85 | ESR1 (0.38) | ESR1ESR2 | |
| SCHEMBL658128 | 0.85 | ESR1 (0.38) | ESR1ESR2 | |
| Ammonia Solution, Strong SCHEMBL8948373 | 0.83 | ESR1 (0.37) | ESR1ESR2 | |
| Ammonia Solution, Strong SCHEMBL28116237 | 0.72 | ESR1 (0.31) | ESR1ESR2 | |
| SCHEMBL25568298 | 0.68 | — | — | |
| SCHEMBL4413629 | 0.68 | ESR1 (0.45) | ESR1ESR2ALDH1A1 | |
| SCHEMBL25568295 | 0.68 | — | — | |
| SCHEMBL540773 | 0.68 | ESR1 (0.38) | ESR1ESR2 | |
| SCHEMBL9127468 | 0.66 | SLC22A1 (0.30) | ESR1 | |
| SCHEMBL28134196 | 0.65 | ESR1 (0.38) | ESR1ESR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2419402-B1 | SYNTHESIS OF 1-AMINO-1,3,3,5,5-PENTAMETHYLCYCLOHEXANE MESYLATE | MERZ PHARMA GMBH & CO KGAA (DE) | 2016-08-31 | — | — | EP | disclosed |
| US-8784847-B2 | Synthesis of 1-amino-1,3,3,5,5,-cyclohexane mesylate | MERZ PHARMA GMBH & CO. KGAA (DE) | 2014-07-22 | — | — | US | disclosed |
| US-20120100184-A1 | SYNTHESIS OF 1-AMINO-1,3,3,5,5,-CYCLOHEXANE MESYLATE | MERZ PHARMA GMBH & CO.KGAA (DE) | 2012-04-26 | — | — | US | disclosed |
| US-20120093866-A1 | FORMULATION FOR STABILIZING PROTEINS, WHICH IS FREE OF MAMMALIAN EXCIPIENT | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-04-19 | — | — | US | disclosed |
| EP-2419402-A1 | SYNTHESIS OF 1-AMINO-1,3,3,5,5-PENTAMETHYLCYCLOHEXANE MESYLATE | Merz Pharma GmbH & Co. KGaA (DE) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010118889-A1 | SYNTHESIS OF 1-AMINO-1,3,3,5,5-PENTAMETHYLCYCLOHEXANE MESYLATE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120093866-A1 | FORMULATION FOR STABILIZING PROTEINS, WHICH IS FREE OF MAMMALIAN EXCIPIENT | CETP, SMURF1, CERT1 | ESR1 4440/4885ESR2 4207/4885ALDH1A1 3582/4885 |
| US-20120100184-A1 | SYNTHESIS OF 1-AMINO-1,3,3,5,5,-CYCLOHEXANE MESYLATE | MSMO1, ACMSD, MAT1A | ESR1 2860/4885ESR2 2241/4885ALDH1A1 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.